Biotronik said today it launched the CardioMessenger Smart portable cardiac pacing device monitor in the U.S.
The CardioMessenger Smart is a portable device designed to allow pacemakers, implantable cardioverter defibrillators and insertable cardiac monitors to stay connected remotely to their monitoring physicians.
“The clinical and economic benefits of remote monitoring have been well established over a decade of clinical studies. But these benefits are only realized if patients consistently use the technology. When we make the remote monitoring process easy for patients, we increase the likelihood of patient adherence, which has been demonstrated to improve health outcomes,” Trust trial lead investigator Dr. Niraj Varma said in a prepared statement.
The CardioMessenger Smart is designed to allow for the automatic transmission of vital information from a patient’s cardiac implant to their physician through Biotronik’s home monitoring service.
Daily reports are automatically sent and alerts can be customized according to physician’s specifications, Biotronik said.
“Biotronik pioneered modern wireless remote monitoring technologies in the year 2000 and we continue to invest in advancements that make life more enjoyable for patients living with cardiac conditions. The Trust study demonstrated that Biotronik Home Monitoring delivers greater than 90% reliability1 of daily remote monitoring transmissions, providing more complete data for physicians to use in optimizing patient care. CardioMessenger Smart is Biotronik’s latest Home Monitoring innovation that provides market-leading performance,” prez Marlou Janssen said in prepared remarks.
Earlier this month, Biotronik said it enrolled the 1st patient in its BiostemI trial looking to compare the safety and efficacy of its Orsiro hybrid drug-eluting stent with Abbott‘s (NYSE:ABT) Xience Xpedition in treating ST-segment elevation myocardial infarction.
The company is touting the trial as the largest investigator-initiated study pitting the Orsiro stent against the Xience Xpedition. The randomized, multi-center trial is slated to enroll 1,250 patients at 16 centers in Switzerland and Italy, Biotronik said.
